Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Determination of True ERBB2

Determination of True ERBB2 RESEARCH ARTICLE Determination of True ERBB2 Gene Amplification in Breast Cancer by Quantitative PCR Using a Reference and a Novel Control Gene Cristina Chamizo, PhD, Federico Rojo, MD, PhD, and Juan Madoz-Gu´rpide, PhD and the contingency study assigned a k value of 0.729 for their Abstract: Human epidermal growth factor receptor 2 (ERBB2/ correlation. A receiver operating characteristic analysis was used HER2) is amplified and overexpressed in 20% to 25% of breast to determine the optimal cut-off point for ERBB2 amplification, carcinomas, correlates with poor outcome, and is an indication which was estimated at a QPA = 1.53 (sensitivity = 0.863; spe- for treatment with trastuzumab. Accurate assessment of ERBB2 cificity = 0.944). Our data conclude that the QPA is able to status is crucial for proper prognosis and to offer appropriate determine ERBB2 gene status with high accuracy, while also treatment for patients. ERBB2 status is generally determined by overcoming the limitations of conventional techniques and immunohistochemistry or fluorescence in situ hybridization providing better cost-effectiveness. (FISH), and sporadically by quantitative real-time polymerase Key Words: breast cancer, ERBB2/HER2 amplification, quan- chain reaction (PCR). We developed a new algorithm, termed titative real-time PCR, predictive marker quantitative PCR algorithm (QPA) score, http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Applied Immunohistochemistry & Molecular Morphology Wolters Kluwer Health

Determination of True ERBB2

Applied Immunohistochemistry & Molecular Morphology , Volume Publish Ahead of Print – Mar 1, 2015

Loading next page...
 
/lp/wolters-kluwer-health/determination-of-true-erbb2-gYK7b5wM3I
Copyright
Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
ISSN
1541-2016
DOI
10.1097/PAI.0000000000000160
pmid
25789534
Publisher site
See Article on Publisher Site

Abstract

RESEARCH ARTICLE Determination of True ERBB2 Gene Amplification in Breast Cancer by Quantitative PCR Using a Reference and a Novel Control Gene Cristina Chamizo, PhD, Federico Rojo, MD, PhD, and Juan Madoz-Gu´rpide, PhD and the contingency study assigned a k value of 0.729 for their Abstract: Human epidermal growth factor receptor 2 (ERBB2/ correlation. A receiver operating characteristic analysis was used HER2) is amplified and overexpressed in 20% to 25% of breast to determine the optimal cut-off point for ERBB2 amplification, carcinomas, correlates with poor outcome, and is an indication which was estimated at a QPA = 1.53 (sensitivity = 0.863; spe- for treatment with trastuzumab. Accurate assessment of ERBB2 cificity = 0.944). Our data conclude that the QPA is able to status is crucial for proper prognosis and to offer appropriate determine ERBB2 gene status with high accuracy, while also treatment for patients. ERBB2 status is generally determined by overcoming the limitations of conventional techniques and immunohistochemistry or fluorescence in situ hybridization providing better cost-effectiveness. (FISH), and sporadically by quantitative real-time polymerase Key Words: breast cancer, ERBB2/HER2 amplification, quan- chain reaction (PCR). We developed a new algorithm, termed titative real-time PCR, predictive marker quantitative PCR algorithm (QPA) score,

Journal

Applied Immunohistochemistry & Molecular MorphologyWolters Kluwer Health

Published: Mar 1, 2015

There are no references for this article.